Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2879-2885

  Shelton, Edward ^a,b   Allegretti, Jessica R ^b,c   Stevens, Betsy ^a   Lucci, Matthew ^c   Khalili, Hamed ^a,b   Nguyen, Deanna D ^a,b   Sauk, Jenny ^a,b   Giallourakis, Cosmas ^a,b   Garber, John ^a,b   Hamilton, Matthew J ^b,c   Tomczak, Michal ^b,c   Makrauer, Fredrick ^b,c   Burakoff, Robert B ^b,c   Levine, Jonathan ^b,c   De Silva, Punyaganie ^b,c   Friedman, Sonia ^b,c   Ananthakrishnan, Ashwin ^a,b   Korzenik, Joshua R ^b,c   Yajnik, Vijay ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Crohn's disease; ulcerative colitis; vedolizumab

Indexed keywords

C REACTIVE PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; CORTICOSTEROID; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ADULT; ANUS FISTULA; ARTHRALGIA; ARTICLE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; INFECTIOUS COMPLICATION; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROCTOCOLECTOMY; PYODERMA GANGRENOSUM; RASH; REMISSION; RETINA VEIN OCCLUSION; STOMA; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84947714237     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000561     Document Type: Article

References (29)

1. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
2. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcer-ative colitis and Crohn's disease? Clin Exp Gastroenterol. 2014;7:163-172.
3. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
4. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409-1422.
5. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
6. Clifford DB. Natalizumab and PML: a risky business? Gut. 2008;57: 1347-1349.
7. Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gasteroenterol Hepatol. 2012;10:1002-1007.
8. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
9. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
10. Shen B, Achkar J-P, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748-753.
11. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
12. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
13. Sandborn WJ, Feagan B, Reinisch W, et al. P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6. J Crohns Colitis. 2014;8: S274-S275.
14. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-627.
15. Cominelli F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med. 2013;369:775-776.
16. de Silva PSA, Nguyen DD, Sauk J, et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:459-466.
17. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
18. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7:717-722.
19. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after inflix-imab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219-225.
20. Lee K-M, Jeen YT, Cho JY, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gasteroenterol Hepatol. 2013;28:1829-1833.
21. Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340-348.
22. Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biol Targets Ther. 2013;7:123-130.
23. Colombel J-F, Loftus EV, Siegel CA, et al. Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1. Gastroenterology. 2015;148(suppl 1):277-278.
24. Colombel J-F, Loftus EV Jr, Siegel CA, et al. Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn's disease in GEMINI 2. Gastroenterology. 2015;148(suppl 1):277.
25. Bryant R, Sandborn W, Travis S. Introducing vedolizumab to clinical practice: who, when, and How? J Crohns Colitis. 2015;9:356-366.
26. Colombel JF, Sands BE, Feagan BG, et al. 643 Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Gastroenterology. 2015;144:S-113.
27. Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151-1159.
28. Yajnik V, Khan N, Dubinksky M, et al. Efficacy and safety of vedolizu-mab with advancing age in patients with ulcerative colitis: Results from the GEMINI 1 study. Gastroenterology. 2015;148(suppl 1):278-279.
29. Colombel JF, Sands BE, Hanauer S. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Am J Gasteroenterol. 2013;108:S500-S561.